tiprankstipranks
Advertisement
Advertisement

NKTX Stock Latest News

Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
Company AnnouncementsNkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
10d ago
8K
NKTX
Nkarta price target lowered to $9 from $25 at Evercore ISI
PremiumThe Fly
Nkarta price target lowered to $9 from $25 at Evercore ISI
1M ago
NKTX
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
PremiumRatings
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
1M ago
NKTX
Nkarta reports Q1 EPS (37c), consensus (37c)
PremiumThe Fly
Nkarta reports Q1 EPS (37c), consensus (37c)
1M ago
NKTX
Nkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
PremiumRatings
Nkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
2M ago
NKTX
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
PremiumThe FlyNkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
2M ago
NKTX
Nkarta price target lowered to $12 from $14 at Mizuho
Premium
The Fly
Nkarta price target lowered to $12 from $14 at Mizuho
3M ago
NKTX
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
Premium
Ratings
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
3M ago
NKTX
Nkarta price target raised to $11 from $10 at Needham
PremiumThe Fly
Nkarta price target raised to $11 from $10 at Needham
3M ago
NKTX
Nkarta Launches $100 Million At-the-Market Stock Offering
PremiumCompany Announcements
Nkarta Launches $100 Million At-the-Market Stock Offering
3M ago
8K
NKTX
Nkarta files $350M mixed securities shelf
PremiumThe Fly
Nkarta files $350M mixed securities shelf
3M ago
NKTX
Nkarta reports Q4 EPS (37c), consensus (29c)
PremiumThe Fly
Nkarta reports Q4 EPS (37c), consensus (29c)
3M ago
NKTX
Is NKTX a Buy, Before Earnings?
PremiumPre-EarningsIs NKTX a Buy, Before Earnings?
3M ago
NKTX
Nkarta price target lowered to $11 from $12 at Stifel
Premium
The Fly
Nkarta price target lowered to $11 from $12 at Stifel
7M ago
NKTX
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
Premium
Ratings
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
7M ago
NKTX
Nkarta Advances NKX019 Program Amid Financial Stability
PremiumCompany Announcements
Nkarta Advances NKX019 Program Amid Financial Stability
7M ago
NKTX
Nkarta reports Q3 EPS (29c), consensus (30c)
PremiumThe Fly
Nkarta reports Q3 EPS (29c), consensus (30c)
7M ago
NKTX
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
PremiumCompany Announcements
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
8M ago
NKTX
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
PremiumCompany Announcements
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
8M ago
NKTX
Nkarta price target lowered to $12 from $14 at Stifel
PremiumThe FlyNkarta price target lowered to $12 from $14 at Stifel
10M ago
NKTX
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
Premium
Ratings
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
10M ago
NKTX
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
Premium
Ratings
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
10M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >